A Phase I/II Study of Natalizumab as a Single Agent in Children, Adolescents and Young Adults With Recurrent, Refractory or Progressive Pulmonary Metastatic Osteosarcoma
Latest Information Update: 21 Jan 2025
At a glance
- Drugs Natalizumab (Primary)
- Indications Lung cancer; Osteosarcoma
- Focus Adverse reactions; Proof of concept
Most Recent Events
- 15 Jan 2025 Status changed from recruiting to withdrawn prior to enrolment due to No accruals
- 10 Jul 2024 Planned End Date changed from 1 Oct 2025 to 1 Oct 2026.
- 10 Jul 2024 Planned primary completion date changed from 1 Dec 2024 to 1 Dec 2025.